No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark ...

No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in ...

MBX Biosciences offers a unique prodrug approach with three promising candidates targeting hypoparathyroidism, post-bariatric hypoglycemia, and obesity - two of its three drug candidates are GLP ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Viking Therapeutics faces tough competition in the obesity drug market dominated by Eli Lilly and Novo Nordisk, with first-mover advantages hard to overcome. VK2735 shows promising early efficacy ...

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the ...